SWOG clinical trial number
CTSU/A021806

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Closed
Phase
Abbreviated Title
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Status Notes
This study is active in SWOG as of July 1, 2020 and new patient enrollment will be permanently closed on Monday, December 1, 2025, at 4:00 PM ET.
Activated
07/01/2020
Closed
12/01/2025

Research committees

Gastrointestinal Cancer

Eligibility Criteria Expand/Collapse

Please see eligibility criteria in protocol on www.CTSU.org

Publication Information Expand/Collapse

2023

Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer

A Chawla;Q Shi;A Ko;M Beg;A Varghese;M Noel;M Bloomston;F Ahmed;W Frankel;J Dixon;X Carrero;A Shergill;J Crawley;O Akin;D Renouf;G Zogopoulos;J Hubbard;J Meyerhardt;E O'Reilly;C Ferrone J Clin Oncol 41, 2023 (suppl 16; abstr TPS4204); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
54%
Open
Phase